Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Impact of Large Cells and Ki-67% on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - Results from a Multicenter Cohort Study

Narendranath Epperla, Natalie S. Grover, Kaitlin Annunzio, Marcus P Watkins, Pallawi Torka, Reem Karmali, Andrea Carolina Anampa-Guzmán, Timothy S. Oh, Heather Reves, Montreh Tavakkoli, Emily Hansinger, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Nancy L. Bartlett, Geoffrey P. Shouse, Adam J Olszewski

Blood (2023) 142 (Supplement 1): 266.

https://doi.org/10.1182/blood-2023-185152

Published: 2023

Journal Articles

Impact of Diagnosis to Treatment Interval on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - a US Multisite Study

Narendranath Epperla, Kaitlin Annunzio, Geoffrey P. Shouse, Natalie S. Grover, Pallawi Torka, Marcus P Watkins, Andrea Carolina Anampa-Guzmán, Timothy S. Oh, Heather Reves, Montreh Tavakkoli, Emily Hansinger, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Reem Karmali, Nancy L. Bartlett, Adam J Olszewski

Blood (2023) 142 (Supplement 1): 5159.

https://doi.org/10.1182/blood-2023-185205

Published: 2023

Journal Articles

Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial

Yazeed Sawalha, Rina Li Welkie, Anna Krivenko, Brian Hess, Audrey M. Sigmund, Timothy Voorhees, Walter Hanel, David A. Bond, John C Reneau, Narendranath Epperla, Lapo Alinari, Jonathan E. Brammer, Beth Christian, Robert Baiocchi, Kami J. Maddocks

Blood (2023) 142 (Supplement 1): 6226.

https://doi.org/10.1182/blood-2023-182941

Published: 2023

Journal Articles

Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers

Blood (2023) 142 (Supplement 1): 382.

https://doi.org/10.1182/blood-2023-182389

Published: 2023

Journal Articles

Differences in Observed Toxicities for Adolescent and Young Adult Patients with Aggressive Mature B-Cell Lymphomas Treated at Adult Versus Pediatric Cancer Center - a Comparative Cohort Study

Allison M Lehanka, Ann Kebede, Neda Amirmokhtari, Joseph R Stanek, Narendranath Epperla, Beth Christian, Robert Baiocchi, Timothy Voorhees, Kami J. Maddocks, Yazeed Sawalha, John C Reneau, Jonathan E. Brammer, Audrey M. Sigmund, Faye Willen, Nick Yeager, Anthony N. Audino, David A. Bond

Blood (2023) 142 (Supplement 1): 3116.

https://doi.org/10.1182/blood-2023-187194

Published: 2023

Journal Articles

Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers

Blood (2023) 142 (Supplement 1): 5147.

https://doi.org/10.1182/blood-2023-185182

Published: 2023

Journal Articles

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170

Pier Luigi Zinzani, Catherine Thieblemont, Vladimir Melnichenko, Krimo Bouabdallah, Jan Walewski, Alejandro Majlis, Laura Fogliatto, A. Martin Garcia-Sancho, Beth Christian, Zafer Gulbas, Muhit Özcan, Guilherme Fleury Perini, Herve Ghesquieres, Margaret A. Shipp, Seth Thompson, Samhita Chakraborty, Patricia Marinello, Philippe Armand

Blood (2023) 142 (2): 141–145.

https://doi.org/10.1182/blood.2022019340

Published: 2023

Journal Articles

Impact of Monoclonal Protein at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma: A Multicenter Cohort Study

Narendranath Epperla, Qiuhong Zhao, Lauren Shea, Reem Karmali, Pallawi Torka, Timothy Seijung Oh, Andrea Anampa-Guzman, Ximena Jordan Bruno, Elvira Umyarova, Kathryn Lindsey, Irl Brian Greenwell, Sayan Mullick Chowdhury, Yazeed Sawalha, Beth Christian, Natalie S. Grover, Nancy L. Bartlett, Adam J. Olszewski

Blood (2022) 140 (Supplement 1): 420–422.

https://doi.org/10.1182/blood-2022-158771

Published: 2022

Journal Articles

Early Relapse within 24 Months after Frontline Systemic Therapy (POD24) Is Associated with Worse Survival in Patients with Marginal Zone Lymphoma: A US Multisite Study

Narendranath Epperla, Rui Li, Pallawi Torka, Lauren Shea, Reem Karmali, Andrea Anampa-Guzman, Timothy Seijung Oh, Kathryn Lindsey, Irl Brian Greenwell, Sayan Mullick Chowdhury, Kaitlin Annunzio, Beth Christian, Geoffrey Shouse, Alex F. Herrera, Nancy L. Bartlett, Natalie S. Grover, Adam J. Olszewski

Blood (2022) 140 (Supplement 1): 1926–1928.

https://doi.org/10.1182/blood-2022-166785

Published: 2022

Journal Articles

Nanochip Technology for Monitoring Chemotherapy Response Using Extracellular RNAs and Proteins in Patient Plasma with Diffuse Large B-Cell Lymphoma As Biomarkers

Narendranath Epperla, Xinyu Wang, Hong Li, David A. Bond, Yazeed Sawalha, John C. Reneau, Timothy J. Voorhees, Kami J. Maddocks, Beth Christian, Walter Hanel, Lapo Alinari, Lalit Sehgal, Robert A. Baiocchi, James L. Lee

Blood (2022) 140 (Supplement 1): 11873–11875.

https://doi.org/10.1182/blood-2022-164907

Published: 2022

Journal Articles

Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Srichandhana Rajamouli, Eric McLaughlin, Walter Hanel, David A. Bond, Yazeed Sawalha, Timothy J. Voorhees, Lapo Alinari, Lalit Sehgal, Kami J. Maddocks, Beth Christian, Daniel Jones, Narendranath Epperla

Blood (2022) 140 (Supplement 1): 6659–6660.

https://doi.org/10.1182/blood-2022-166988

Published: 2022

Journal Articles

Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma

Kaitlin Annunzio, Natalie S. Grover, Rui Li, Daniel Jones, Walter Hanel, Beth Christian, Adam J. Olszewski, Narendranath Epperla

Blood (2022) 140 (Supplement 1): 3644–3645.

https://doi.org/10.1182/blood-2022-164892

Published: 2022

Journal Articles

Acalabrutinib Plus Rituximab with or without Lenalidomide in Patients with Follicular Lymphoma: A Multipart, Open-Label, Phase 1b Trial

Paolo Strati, Beth Christian, Peter Martin, Becky Champion, Morton Coleman, Richy Agajanian, Sonali M. Smith, Parameswaran Venugopal, Izidore S. Lossos, Robert Kridel, Roser Calvo, Kara Higgins, Deborah M. Stephens

Blood (2022) 140 (Supplement 1): 3606–3608.

https://doi.org/10.1182/blood-2022-159158

Published: 2022

Journal Articles

Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

Pier Luigi Luigi Zinzani, Catherine Thieblemont, Vladimir Melnichenko, Krimo Bouabdallah, Jan Waleswski, Alejandro Majlis, Laura Fogliatto, Alejandro Martin Garcia-Sancho, Beth Christian, Zafer Gulbas, Muhit Özcan, Guilherme Fleury Perini, Gilles Salles, Margaret A. Shipp, Seth Thompson, Samhita Chakraborty, Patricia Marinello, Philippe Armand

Blood (2021) 138 (Supplement 1): 306.

https://doi.org/10.1182/blood-2021-148082

Published: 2021

Journal Articles

Outcomes of Patients with Diffuse Large B Cell and High-Grade B Cell Lymphomas with Synchronous CNS and Systemic Involvement at Diagnosis Treated with High-Dose Methotrexate and R-CHOP: A Single-Center Retrospective Study

Megan Fleming, Ying Huang, Emily Dotson, David A. Bond, John C. Reneau, Narendranath Epperla, Jonathan E. Brammer, Beth Christian, Lapo Alinari, Robert Baiocchi, Kami J. Maddocks, Yazeed Sawalha

Blood (2021) 138 (Supplement 1): 1425.

https://doi.org/10.1182/blood-2021-148662

Published: 2021

Journal Articles

Randomized Phase 2 Trial of Ofatumumab and Bendamustine Versus Ofatumumab, Bendamustine, and Bortezomib Induction and Maintenance Therapy in Patients (pts) with Previously Untreated High Risk Follicular Lymphoma (FL): Results from CALGB 50904 (Alliance)

Kristie A. Blum, MD, Sin-Ho Jung, PhD, Ian Barak, MS, Eric D. Hsi, MD, Nina D. Wagner-Johnston, MD, Beth Christian, MD, Jim Atkins, Bruce D. Cheson, MD, John P. Leonard, MD, Nancy L. Bartlett, MD

Blood (2017) 130 (Supplement 1): 485.

https://doi.org/10.1182/blood.V130.Suppl_1.485.485

Published: 2017

Journal Articles

Efficacy and Safety of Pembrolizumab in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMBCL): Updated Analysis of the Keynote-170 Phase 2 Trial

Pier Luigi Zinzani, MD, Catherine Thieblemont, MD PhD, Vladimir Melnichenko, Krimo Bouabdallah, Jan Walewski, MD PhD, Alejandro Majlis, MD, Laura Fogliatto, MD, Dolores Caballero, MD PhD, Beth Christian, MD, Zafer Gulbas, MD, Muhit Özcan, MD, Gilles Andre Salles, MD PhD, Margaret A. Shipp, MD, Arkendu Chatterjee, Robert J Orlowski, Arun Balakumaran, MD PhD, Philippe Armand, MD PhD

Blood (2017) 130 (Supplement 1): 2833.

https://doi.org/10.1182/blood.V130.Suppl_1.2833.2833

Published: 2017

Journal Articles

Outcomes of Patients with Primary Refractory Mantle Cell Lymphoma, a Single Center Retrospective Study

David A Bond, MD, Ying Huang, MA, MS, Beth Christian, MD, Kami J. Maddocks, MD

Blood (2017) 130 (Supplement 1): 1503.

https://doi.org/10.1182/blood.V130.Suppl_1.1503.1503

Published: 2017

Journal Articles

Checkpoint inhibition in CNS lymphoma

Beth Christian

Blood (2017) 129 (23): 3045–3046.

https://doi.org/10.1182/blood-2017-04-777797

Published: 2017

Journal Articles

A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma

Kami Maddocks, Beth Christian, Samantha Jaglowski, Joseph Flynn, Jeffery A. Jones, Pierluigi Porcu, Lai Wei, Cynthia Jenkins, Gerard Lozanski, John C. Byrd, Kristie A. Blum

Blood (2015) 125 (2): 242–248.

https://doi.org/10.1182/blood-2014-08-597914

Published: 2015

NARROW

Impact of Large Cells and Ki-67% on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - Results from a Multicenter Cohort Study

Impact of Diagnosis to Treatment Interval on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - a US Multisite Study

Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial

Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers

Differences in Observed Toxicities for Adolescent and Young Adult Patients with Aggressive Mature B-Cell Lymphomas Treated at Adult Versus Pediatric Cancer Center - a Comparative Cohort Study

Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170

Impact of Monoclonal Protein at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma: A Multicenter Cohort Study

Early Relapse within 24 Months after Frontline Systemic Therapy (POD24) Is Associated with Worse Survival in Patients with Marginal Zone Lymphoma: A US Multisite Study

Nanochip Technology for Monitoring Chemotherapy Response Using Extracellular RNAs and Proteins in Patient Plasma with Diffuse Large B-Cell Lymphoma As Biomarkers

Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma

Acalabrutinib Plus Rituximab with or without Lenalidomide in Patients with Follicular Lymphoma: A Multipart, Open-Label, Phase 1b Trial

Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

Outcomes of Patients with Diffuse Large B Cell and High-Grade B Cell Lymphomas with Synchronous CNS and Systemic Involvement at Diagnosis Treated with High-Dose Methotrexate and R-CHOP: A Single-Center Retrospective Study

Randomized Phase 2 Trial of Ofatumumab and Bendamustine Versus Ofatumumab, Bendamustine, and Bortezomib Induction and Maintenance Therapy in Patients (pts) with Previously Untreated High Risk Follicular Lymphoma (FL): Results from CALGB 50904 (Alliance)

Efficacy and Safety of Pembrolizumab in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMBCL): Updated Analysis of the Keynote-170 Phase 2 Trial

Outcomes of Patients with Primary Refractory Mantle Cell Lymphoma, a Single Center Retrospective Study

Checkpoint inhibition in CNS lymphoma

A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only